No Data
Shenzhen Kangtai Biological Products (300601.SZ): Minhai Biological's 20-valent pneumococcal polysaccharide conjugate vaccine initiates Phase I clinical trials.
Great Long Special Report, November 25th| Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary, Peking Minhai Biological Technology Co., Ltd. (hereinafter referred to as "Minhai Biological"), has completed the preparation for Phase I clinical trial of the 20-valent pneumococcal polysaccharide conjugate vaccine developed, initiated the Phase I clinical trial, and recently successfully completed the first subject's enrollment. The 20-valent pneumococcal polysaccharide conjugate vaccine is suitable for infants and children aged 2 months to 5 years old. After vaccination with this vaccine, the body can generate an immune response to prevent infectious diseases caused by 20 serotypes of pneumococcal serotypes. Currently, the 20-valent pneumococcal polysaccharide conjugate vaccine has been marketed overseas.
Shenzhen Kangtai Biological Products (300601.SZ): The clinical trial application for bivalent inactivated rotavirus vaccine (Vero cells) has been accepted.
Announcement from shenzhen kangtai biological products (300601.SZ), the company's wholly-owned subsidiary Peking Minhai Biotechnology Co., Ltd. (referred to as "...
Shenzhen Kangtai Biological Products' (SZSE:300601) Profits Appear To Have Quality Issues
Kangtai Biotech: Report for the third quarter of 2024
shenzhen kangtai biological products (300601.SZ): The net income for the first three quarters was 0.351 billion yuan, a year-on-year decrease of 49.63%.
On October 25th, Gelunhui reported that Shenzhen Kangtai Biological Products (300601.SZ) released its third quarter report. In the first three quarters of 2024, the company achieved revenue of 2.018 billion yuan, a decrease of 18.11% year-on-year; net income attributable to shareholders of the listed company was 0.351 billion yuan, a decrease of 49.63% year-on-year; net income after deducting non-recurring gains and losses was 0.304 billion yuan, a decrease of 49.27% year-on-year; basic earnings per share were 0.31 yuan per share.
The Three-year Loss for Shenzhen Kangtai Biological Products (SZSE:300601) Shareholders Likely Driven by Its Shrinking Earnings
The Three-year Shareholder Returns and Company Earnings Persist Lower as Shenzhen Kangtai Biological Products (SZSE:300601) Stock Falls a Further 4.4% in Past Week
